Summary:

- The article discusses the work of Pluri, a biotechnology company focused on developing therapies to address aging and age-related diseases. Pluri's co-founders, Yaky Yanay and James "Jim" Roosevelt, are interviewed about the company's mission and approach.

- Pluri is developing therapies that aim to extend the human healthspan by targeting the biological processes of aging. The company's research is focused on regenerative medicine, including the use of pluripotent stem cells and other innovative technologies to promote tissue repair and rejuvenation.

- The article highlights Pluri's efforts to advance the field of longevity science and its potential to transform the healthcare landscape by providing new therapeutic options for age-related conditions. The company's work is positioned as a promising step towards improving quality of life and extending the healthy, active years of individuals.